In response to reports of a shortage of one C1 esterase inhibitor product on the market, BioRx affirmed today that its supply of Berinert® remains strong and can immediately accommodate increased demand. The statement was in response to publicly reported production delays affecting the only other commercially available C1-INH product. C1-INH products are FDA-approved for the treatment of hereditary angioedema.
Production delays have reportedly impacted the supply of one C1-INH product as demand for both it and Berinert continue to grow. Conversely, according to BioRx, production of Berinert remains strong enough to meet increasing demand in the United States.
“The HAE community is very small, so news and rumors travel pretty fast,” said Eric Hill, co-founder of BioRx. “We just want to be sure that both patients and physicians are aware that our supply of C1 inhibitor product, Berinert, is more than adequate to meet their needs.” While each brand of C1-INH carries the same mechanism of action, they carry a different indication related to the infusion regimen – Berinert for treatment of acute attacks and the other for prophylactic, or preventive, use. Since both products are indicated for the treatment of HAE, however, it is not uncommon for a physician to prescribe either product for the same use, or both for different uses.
Hereditary angioedema (HAE) is a rare, potentially fatal genetic disorder characterized by the deficiency or dysfunction of the plasma protein “C1 esterase inhibitor” (C1-INH). Clinical characteristics of HAE include painful swelling of the extremities, face, trunk, abdomen and upper airway. Before treatment became available, the mortality rate for HAE patients was as high as 30% due to asphyxiation. There are an estimated 11,000 cases in the United States. For more information, visit www.haefreedom.com.
Based in Cincinnati, Ohio, BioRx is one of the nation’s fastest growing providers of specialty pharmaceuticals and infusion services, delivering highly customized care for patients with certain rare and chronic diseases. In addition to serving the HAE community, BioRx offers pharmacy, nursing and education services to patients with bleeding disorders, immune deficiencies, autoimmune disorders, alpha-1 antitrypsin deficiency, and nutritional/digestive disorders. The company’s clinical staff reaches patients and physicians in all 50 states. To learn more about BioRx and its products and services, visit www.biorx.com.